Tetrindole
Clinical data | |
---|---|
ATC code | None |
Identifiers | |
| |
PubChem (CID) | 160020 |
ChemSpider | 140675 |
ChEBI | CHEBI:77799 |
Chemical and physical data | |
Formula | C20H26N2 |
Molar mass | 294.43 g/mol |
3D model (Jmol) | Interactive image |
| |
| |
(what is this?) (verify) |
Tetrindole was a drug candidate that functions by reversibly inhibiting monoamine oxidase A; it was first synthesized in Moscow in the early 1990s.[1] Tetrindole is similar in its chemical structure to pirlindole (Pyrazidol), and metralindole.[2]
References
- ↑ Medvedev, AE; Kirkel, AA; Kamyshanskaya, NS; Moskvitina, TA; Axenova, LN; Gorkin, VZ; Andreeva, NI; Golovina, SM; Mashkovsky, MD (20 January 1994). "Monoamine Oxidase Inhibition by Novel Antidepressant Tetrindole". Biochemical Pharmacology. 47 (2): 303–8. doi:10.1016/0006-2952(94)90021-3. PMID 8304974.
- ↑ Ramsay, RR; Gravestock, MB (March 2003). "Monoamine Oxidases: to Inhibit or Not to Inhibit". Mini Reviews in Medicinal Chemistry. 3 (2): 129–36. doi:10.2174/1389557033405287. PMID 12570845.
This article is issued from Wikipedia - version of the 9/2/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.